| Study | Reason for exclusion |
|---|---|
| Abe 2017 | Post hoc subgroup analyses of an already included trial |
| Abufarag 2010 | Other treatment |
| ACTRN12606000040561 | Wrong intervention |
| Adsit 2017 | Post hoc subgroup analyses of an already included trial |
| Akhyani 2010 | Other treatment |
| Al‐Oudah 2022 | Wrong intervention |
| Altmeyer 1994 | Not plaque‐type psoriasis |
| Angsten 2007 | Not a trial |
| Anonymous 2005 | Not a trial |
| Anonymous 2008 | Not a trial |
| Anonymous 2019 | Not a randomised trial |
| Araujo 2017 | Not moderate‐to‐severe psoriasis |
| Araujo 2019 | Not moderate‐to‐severe psoriasis |
| Arifov 1998 | Not a randomised trial |
| Armati 1972 | Other treatment |
| Asahina 2016 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Augustin 2017 | Dose de‐escalation strategy study |
| Avgerinou 2011 | Not a randomised trial |
| Bachelez 2017 | Post hoc subgroup analyses of an already included trial |
| Bagel 2017a | Open‐label extension restricted to good responders |
| Bagel 2017b | Not a randomised trial |
| Bagel 2017c | Not moderate‐to‐severe psoriasis |
| Bagel 2018b | Not a randomised trial |
| Bagherani 2017 | Commentary/editorial |
| Bagot 1994 | Other treatment |
| Banerjee 2021 | Wrong comparator |
| Bartlett 2008 | Not a trial |
| Barzegari 2004 | Other treatment |
| Batchelor 2009 | Not a trial |
| Bayerl 1992 | Other treatment |
| Beissert 2009 | Other treatment |
| Berbis 1989 | Assessment < 8 weeks |
| Bhat 2017 | Post hoc subgroup analyses of an already included trial |
| Bhuiyan 2010 | Other treatment |
| Bian 2018` | Open‐label extension restricted to good responders |
| Bigby 2004 | Not a trial |
| Bissonnette 2006 | Other treatment |
| Bissonnette 2010 | Other treatment |
| Bissonnette 2015 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Bissonnette 2017a | Open‐label extension restricted to good responders |
| Bissonnette 2017b | Not moderate‐to‐severe psoriasis |
| Bissonnette 2018 | Not moderate‐to‐severe psoriasis |
| Bjerke 1989 | Other treatment |
| Blauvelt 2016a | Ineligible study design |
| Blauvelt 2016b | Open‐label extension restricted to good responders |
| Blauvelt 2017a | Pooled trials |
| Blauvelt 2017b | Open‐label extension restricted to good responders |
| Blauvelt 2017c | Open‐label extension restricted to good responders |
| Blauvelt 2017d | Open‐label extension restricted to good responders |
| Blauvelt 2017e | Pooled trials |
| Blauvelt 2017f | Ineligible study design |
| Blauvelt 2017g | Open‐label extension restricted to good responders |
| Blauvelt 2017h | Open‐label extension restricted to good responders |
| Blauvelt 2017i | Open‐label extension restricted to good responders |
| Blauvelt 2017j | Pooled trials |
| Blauvelt 2017k | Open‐label extension restricted to good responders |
| Blauvelt 2018a | Not a randomised trial |
| Blauvelt 2018b | Open‐label extension restricted to good responders |
| Blauvelt 2018c | Pooled trials |
| Blauvelt 2018d | Pooled trials |
| Blauvelt 2018e | Pooled trials |
| Blauvelt 2018f | Pooled trials |
| Blauvelt 2018g | Pooled trials |
| Blauvelt 2018h | Pooled trials |
| Blauvelt 2020 | Not moderate‐to‐severe psoriasis (good responders selection) |
| Branigan 2017 | Open‐label extension restricted to good responders |
| Brasil 2012 | Ineligible study design |
| Brasil 2013 | Ineligible patient population |
| Brasil 2016 | Ineligible patient population |
| Buono 2020 | Not a randomised trial |
| Burden 2017 | Commentary/editorial |
| Burkhardt 2017 | Ineligible study design |
| Callis Duffin 2017 | Comparison of the same drug with the same dosages |
| Cassano 2006 | Identical dosing regimens |
| Cassano 2010 | Not a trial |
| Cather 2006 | Dose‐ranging after remission |
| Cather 2018 | Ineligible patient population |
| Chakravadhanula 2017 | Ineligible intervention |
| Chapman 2018 | Ineligible study design |
| ChiCTR‐INR‐16009710 | Assessment at 4 weeks |
| ChiCTR2000030273 2020 | Phase 1 trial |
| Chládek 2002 | Basic science (aim of study: to understand the physiopathology of the disease) |
| Chodorowska 1999a | Not a trial |
| Chodorowska 1999b | Not a trial |
| Choi 2017 | Not moderate‐to‐severe psoriasis |
| Crowley 2018a | Not moderate‐to‐severe psoriasis |
| Crowley 2018b | Open‐label extension restricted to good responders |
| CTRI/2018/01/011373 | 2 different schemas of administration (same drug, same dosage) |
| CTRI/2020/07/026598 2020 | 2 different schemas of administration (same drug, same dosage) |
| CTRI/2020/12/029472 2020 | Wrong intervention |
| CTRI/2020/12/029611 | Same intervention |
| De Jong 2003 | Other treatment |
| De Mendizabal 2017 | Post hoc subgroup analyses of an already included trial |
| Dubiel 1972 | Not a trial |
| Duffin 2016 | Comparison of 2 different ways of drug injection for the same drug and the same dosage |
| Duffin 2017 | Ineligible study design |
| Ecker‐Schlipf 2009 | Other treatment |
| Edson‐Heredia 2013 | Post hoc subgroup analyses of an already included trial |
| Egeberg 2016 | Commentary/editorial |
| Elewski 2007 | Pooled trials |
| Elewski 2017 | Post hoc subgroup analyses of an already included trial |
| Elewski 2018a | Ineligible study design |
| Elewski 2018b | Ineligible study design |
| Ellis 1986 | Assessment < 8 weeks |
| Ellis 2001 | Another intervention |
| Ellis 2002 | Medico‐economic study |
| Ellis 2012 | Other treatment |
| Engst 1989 | Assessment < 8 weeks |
| Erkko 1997 | Basic science (aim of study: to understand the physiopathology of the disease) |
| EUCTR2007‐004328‐18‐FR | Ineligible intervention |
| EUCTR2012‐005685‐35‐DE | Withdrawn trial, NCT01815723 |
| EUCTR2016‐001593‐15‐ES | Withdrawn trial, DEEP Study |
| EUCTR2016‐003592‐21‐GB | Withdrawn trial |
| EUCTR2018‐001021‐10‐SE | Not moderate‐to‐severe psoriasis |
| EUCTR2019‐000817‐35‐DE | Not moderate‐to‐severe psoriasis |
| EUCTR2021‐000542‐18‐LV | Not moderate‐to‐severe psoriasis |
| EUCTR2022‐000695‐19‐LT | Not moderate‐to‐severe psoriasis |
| EXCEED 2021 | RCT dedicated to psoriatic arthritis. The randomisation was not stratified on plaque psoriasis with BSA > 10% or PASI ≥ 10 but on psoriatic plaque of ≥ 2 cm diameter. |
| Ezquerra 2007 | Other treatment |
| Feldman 2017 | Not moderate‐to‐severe psoriasis |
| Fernandes 2013 | Not a trial |
| Fernandez 2017 | Not a randomised trial |
| Finzi 1993 | Other treatment |
| Fitz 2018 | Post hoc subgroup analyses of an already included trial |
| Fleischer 2005 | Other treatment |
| Foley 2017 | Pooled trials |
| Foley 2018 | Pooled trials |
| Fredriksson 1971 | Other treatment |
| Fredriksson 1978 | Other treatment |
| Friedrich 2001 | Other treatment |
| GAIN 2021 | Not moderate‐to‐severe psoriasis |
| Gambichler 2011 | Other treatment |
| Ganguly 2004 | Pooled trials |
| Gil 2003 | Not a randomised trial |
| Gisondi 2020 | Not a randomised trial |
| Glatt 2017 | Ineligible study design |
| Goerz 1978 | Not a trial |
| Gold 2018 | Ineligible study design |
| Goll 2017 | Not moderate‐to‐severe psoriasis |
| Goll 2018 | Ineligible study design |
| Gollnick 1988 | Other treatment |
| Gollnick 1993 | Other treatment |
| Gollnick 2002 | Other treatment |
| Gordon 2014 | Ineligible study design |
| Gordon 2015 | Ineligible study design |
| Gordon 2018a | Open‐label extension restricted to good responders |
| Gordon 2018b | Post hoc subgroup analyses of an already included trial |
| Gordon 2018c | Pooled trials |
| Gordon 2018d | Post hoc subgroup analyses of an already included trial |
| Gottlieb 2002 | Other treatment |
| Gottlieb 2003b | Other treatment |
| Gottlieb 2003c | Open‐label extension restricted to good responders |
| Gottlieb 2004b | Pooled trials |
| Gottlieb 2005 | Other treatment |
| Gottlieb 2006a | Ineligible intervention |
| Gottlieb 2006b | Ineligible intervention |
| Gottlieb 2010 | Cross‐over trial |
| Gottlieb 2016 | Pooled trials |
| Gottlieb 2017a | Not moderate‐to‐severe psoriasis |
| Gottlieb 2017b | Not moderate‐to‐severe psoriasis |
| Gottlieb 2017c | Post hoc subgroup analyses of an already included trial |
| Gottlieb 2017d | Pooled trials |
| Gottlieb 2018a | Pooled trials |
| Gottlieb 2018b | Pooled trials |
| Goupille 1995 | Not a randomised trial |
| Goupille 2018 | Not moderate‐to‐severe psoriasis |
| Griffiths 1998 | Other treatment |
| Griffiths 2002a | Pooled trials |
| Griffiths 2002b | Pooled trials |
| Griffiths 2005 | Pooled trials |
| Griffiths 2010 | Open‐label extension restricted to good responders |
| Griffiths 2016 | Post hoc subgroup analyses of an already included trial |
| Griffiths 2017 | Open‐label extension restricted to good responders |
| Griffiths 2018a | Ineligible study design |
| Griffiths 2018b | Post hoc subgroup analyses of an already included trial |
| Griffiths 2018c | Pooled trials |
| Grim 2000 | Basic science (aim of study: to understand the physiopathology of the disease) |
| Grossman 1994 | Other treatment |
| Guenther 2020 | Not moderate‐to‐severe psoriasis |
| Gulliver 1996 | Not a trial |
| Gupta 2005 | Other treatment |
| Gupta 2007 | Other treatment |
| Gupta 2008 | Other treatment |
| Han 2013 | Other treatment |
| Hashizume 2007 | Comparison of 2 methods of administration |
| Hawkes 2018 | Ineligible study design |
| Heule 1988 | Assessment < 8 weeks |
| Ho 2010 | Other treatment |
| Holzer 2020 | No efficacy or safety assessment ‐ the study assessed cardiovascular outcomes |
| Hsu 2018 | Post hoc subgroup analyses of an already included trial |
| Hunter 1972 | Other treatment |
| Iest 1989 | Not a randomised trial |
| Imafuku 2017 | Post hoc subgroup analyses of an already included trial |
| ISRCTN18043449 | Not moderate‐to‐severe psoriasis |
| Iversen 2018 | Ineligible comparator |
| Jackson 2018 | Ineligible study design |
| Jacobe 2008 | Another intervention |
| JapicCTI‐194706 2019 | Comparison of different schemas of administration (same drug, same dosage) |
| Jin 2017 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Joergensen 2022 | Wrong intervention |
| JPRN‐jRCT2071210135 | Wrong population |
| JPRN‐jRCTs041180012 2018 | Not moderate‐to‐severe psoriasis |
| Kaur 2018 | Not moderate‐to‐severe psoriasis |
| Kavanaugh 2009 | Not a randomised trial |
| Kemeny 2019 | Post hoc subgroup analyses of an already included trial |
| Kimball 2008 | Drug withdrawn for safety reasons |
| Kimball 2011 | Drug withdrawn for safety reasons |
| Kimball 2018 | Ineligible study design |
| Kohm 2022 | Not moderate‐to‐severe psoriasis |
| Koo 1998 | Other treatment |
| Kopp 2015 | Phase 1 trial |
| Korotaeva 2021 | Not moderate‐to‐severe psoriasis |
| Kragballe 1989 | Other treatment |
| Krishnan 2005 | Pooled trials |
| Krishnan 2018 | Pooled trials |
| Kristensen 2017 | Not moderate‐to‐severe psoriasis |
| Krueger 1980 | Other treatment |
| Krueger 2002a | Another intervention |
| Krueger 2002b | Not a trial |
| Krueger 2003 | Not a trial |
| Krueger 2012 | Phase 1 trial |
| Krueger 2015 | Phase 1 trial |
| Krueger 2016a | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Krueger 2016b | Phase I trial |
| Krueger 2022 | Not moderate‐to‐severe psoriasis |
| Krupashankar 2014 | Another intervention |
| Kuijpers 1998 | Other treatment |
| Lajevardi 2015 | Other treatment |
| Lambert 2018 | Post hoc subgroup analyses of an already included trial |
| Langewouters 2005 | Other treatment |
| Langley 2006 | Other treatment |
| Langley 2010 | Other treatment |
| Langley 2016 | Open‐label extension restricted to good responders |
| Langley 2018 | Ineligible study design |
| Langner 2004 | Not plaque‐type psoriasis |
| Lauharanta 1989 | Other treatment |
| Lawrence 1983 | Other treatment |
| Leavell 1970 | Other treatment |
| Lebwohl 2003 | Another intervention |
| Lebwohl 2003a | Pooled trials |
| Lebwohl 2009 | Pooled trials |
| Lebwohl 2012 | Other treatment |
| Lebwohl 2013 | Other treatment |
| Ledo 1988 | Other treatment |
| Legat 2005 | Other treatment |
| Leonardi 2010a | Pooled trials |
| Leonardi 2010b | Not a randomised trial |
| Leonardi 2010c | Pooled trials |
| Leonardi 2011a | Open‐label extension restricted to good responders |
| Leonardi 2011b | Not plaque‐type psoriasis |
| Levell 1995 | Other treatment |
| Li 2018 | Post hoc subgroup analyses of an already included trial |
| Li 2022 | Phase 1 trial |
| Liang 1995 | Assessment < 8 weeks |
| Louw 2017 | Open‐label extension restricted to good responders |
| Lui 2011 | Other treatment |
| Lui 2012 | Other treatment |
| Lynde 2012 | Other treatment |
| Macdonald 1972 | Not a randomised trial |
| Mahrle 1995 | Other treatment |
| Malik 2010 | Other treatment |
| Marecki 2004 | Other treatment |
| Marks 1986 | Not a randomised trial |
| Mate 2017 | Not moderate‐to‐severe psoriasis |
| Mate 2018 | Open‐label extension restricted to good responders |
| McInnes 2013 | Pooled trials |
| McInnes 2017 | Not moderate‐to‐severe psoriasis |
| Mease 2011 | Drug withdrawn for safety reasons |
| Mease 2016a | Not moderate‐to‐severe psoriasis |
| Mease 2016b | Not moderate‐to‐severe psoriasis |
| Mease 2017a | Not moderate‐to‐severe psoriasis |
| Mease 2017b | Not moderate‐to‐severe psoriasis |
| Mease 2017c | Not moderate‐to‐severe psoriasis |
| Mease 2018 | Not moderate‐to‐severe psoriasis |
| Mease 2020 | Not moderate‐to‐severe psoriasis |
| Mease 2022 | Not a randomised study |
| Meffert 1989 | Other treatment |
| Menon 2012 | Basic science (aim of study: to understand the physiopathology of the disease) |
| Menter 2007 | Pooled trials |
| Menter 2014 | Drug withdrawn for safety reasons |
| Menter 2022 | Not moderate‐to‐severe psoriasis |
| Merola 2017 | Post hoc subgroup analyses of an already included trial |
| Merola 2018 | Not moderate‐to‐severe psoriasis |
| Merola 2020 | Not moderate‐to‐severe psoriasis |
| Meyer 2011 | Other treatment |
| Mittal 2009 | Other treatment |
| Moller 2009 | Other treatment |
| Monk 1986 | Not a randomised trial |
| Montgomery 1993 | Other treatment |
| Mrowietz 1991 | The 2 study arms compared the same molecule with the same dosage |
| Mrowietz 2012 | Pooled trials |
| Narang 2012 | Other treatment |
| Nash 2015 | Not moderate‐to‐severe psoriasis |
| NCT00106847 | Dose de‐escalation strategy study |
| NCT00111111 | Dose de‐escalation strategy study |
| NCT00258713 | Ineligible intervention |
| NCT00358670 | Open‐label extension restricted to good responders |
| NCT00377325 | Withdrawn trial |
| NCT00438360 | Open‐label extension restricted to good responders |
| NCT00585650 | Ineligible patient population |
| NCT00645892 | Open‐label extension restricted to good responders |
| NCT00646191 | Open‐label extension restricted to good responders |
| NCT00647400 | Open‐label extension restricted to good responders |
| NCT00832364 | Withdrawn trial |
| NCT01163253 | Not a randomised trial |
| NCT01235442 | Ineligible intervention |
| NCT01276847 | Phase I trial |
| NCT01412944 | Open‐label extension restricted to good responders |
| NCT01443338 | Ineligible comparator |
| NCT01544595 | Open‐label extension restricted to good responders |
| NCT01550744 | Open‐label extension restricted to good responders |
| NCT01624233 | Not a randomised trial |
| NCT01722214 | Not moderate‐to‐severe psoriasis |
| NCT01806597 | Ineligible patient population |
| NCT01815723 | Withdrawn trial |
| NCT01828086 | Phase I trial |
| NCT01936688 | Withdrawn trial |
| NCT02362789 | Withdrawn trial |
| NCT02409667 | Open‐label extension restricted to good responders |
| NCT02798211 | Not moderate‐to‐severe psoriasis |
| NCT03010527 | Open‐label extension restricted to good responders |
| NCT03020199 | Ineligible comparator |
| NCT03025542 | Not moderate‐to‐severe psoriasis at the time of placebo use |
| NCT03073213 | Phase I trial |
| NCT03210259 | Not moderate‐to‐severe psoriasis |
| NCT03482011 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| NCT03598790 | Not moderate‐to‐severe psoriasis |
| NCT04121143 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| NCT04488185 | Withdrawn (low recruitment) |
| NCT04614298 | Trial withdrawn for reconsideration of drug's business |
| NCT04839016 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| NCT04882098 | Not moderate‐to‐severe psoriasis |
| NCT05073315 | Not moderate‐to‐severe psoriasis |
| NCT05184348 | Ineligible intervention |
| NCT05478499 | Not moderate‐to‐severe psoriasis |
| NCT05495568 | Not moderate‐to‐severe psoriasis |
| Nemoto 2018 | Phase I trial |
| Nieboer 1990 | Other treatment |
| Nijsten 2008 | Not a trial |
| Noda 2011 | Not a randomised trial |
| Noor 2017 | Not a randomised trial |
| Novotny 1973 | Not a trial |
| Nyfors 1978 | Not a trial |
| Okubo 2019 | Open‐label extension restricted to good responders |
| Oliver 2021 | Ineligible study design |
| OPT Pivotal‐1 2015 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| OPT Pivotal‐2 2015 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Orfanos 1978 | Other treatment |
| Orfanos 1979 | Other treatment |
| Ortonne 2008 | Comparison of 2 schemes of administration |
| Ortonne 2011 | Other treatment |
| Osamu 2014 | Phase 1 trial |
| Page 2020 | Phase 1 trial |
| Pakozdi 2018 | Post hoc subgroup analyses of an already included trial |
| Papp 2001 | Other treatment |
| Papp 2006 | Other treatment |
| Papp 2008 | Other treatment |
| Papp 2009 | Pooled data |
| Papp 2011a | Pooled trials |
| Papp 2011b | Drug withdrawn for safety reasons |
| Papp 2011c | Drug withdrawn for safety reasons |
| Papp 2012b | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Papp 2012d | Phase 1 trial |
| Papp 2012e | Pooled trials |
| Papp 2017c | Open‐label extension restricted to good responders |
| Papp 2018a | Ineligible outcomes |
| Papp 2018b | Ineligible outcomes |
| Park 2013 | Other treatment |
| Paul 2012 | Other treatment |
| Paul 2014 | Other treatment |
| Paul 2018 | Pooled trials |
| Perks 2017 | Ineligible study design |
| Pettit 1979 | Assessment < 8 weeks |
| Petzelbauer 1990 | Not a randomised trial |
| Piascik 2003 | Not a trial |
| Ports 2013 | Other treatment |
| Puig 2018 | Ineligible outcomes |
| Punwani 2012 | Other treatment |
| Rabasseda 2012 | Not a trial |
| Radmanesh 2011 | Comparison of 2 schemes of administration |
| Raman 1998 | Other treatment |
| Reich 2004 | Ineligible intervention |
| Reich 2011 | Pooled trials |
| Reich 2014 | Other treatment |
| Reich 2016a | Ineligible study design |
| Reich 2016b | Ineligible study design |
| Reich 2017a | Ineligible study design |
| Reich 2017b | Open‐label extension restricted to good responders |
| Reich 2017c | Pooled trials |
| Reich 2018a | Ineligible outcomes |
| Reich 2018b | Long‐term follow‐up of patients included in UNCOVER‐3 (at baseline not moderate‐to‐severe psoriasis and no control group) |
| Reich 2018c | Open‐label extension restricted to good responders |
| Reich 2019 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Reitamo 1999 | Other treatment |
| Reitamo 2001 | Other treatment |
| Rim 2003 | Other treatment |
| Rinsho Iyaku 1991 | Other treatment |
| Ritchlin 2006a | Not a randomised trial |
| Ritchlin 2006b | Not a randomised trial |
| Romiti 2017 | Post hoc subgroup analyses of an already included trial |
| RPCEC00000201 | Ineligible intervention |
| Ryan 2018 | Not moderate‐to‐severe psoriasis |
| Saeki 2017 | Not a randomised trial |
| Salim 2006 | Other treatment |
| Scholl 1981 | Other treatment |
| Schopf 1998 | Other treatment |
| Schulze 1991 | Other treatment |
| Shintani 2011 | Comparison of 2 schemes of administration |
| Shiohara 1992 | Not a trial |
| Shupack 1997 | Not a trial |
| Simonova 2005 | Other treatment |
| Sinclair 2017 | Pooled trials |
| Sofen 2011 | Basic science (aim of study: to understand the physiopathology of the disease) |
| Sofen 2014 | Phase 1 trial |
| Soung 2022 | Not moderate‐to‐severe psoriasis |
| Spadaro 2008 | Not a trial |
| Spuls 2012 | Not a trial |
| Stein Gold 2018 | Not moderate‐to‐severe psoriasis |
| Stein Gold 2021 | Not moderate‐to‐severe psoriasis |
| Sticherling 1994 | Not a trial |
| Strober 2004 | Not a trial |
| Strober 2012 | Not a randomised trial |
| Strober 2017a | Pooled trials |
| Strober 2017b | Not moderate‐to‐severe psoriasis |
| Strober 2017c | Ineligible outcomes |
| Strober 2018 | Ineligible study design |
| Sun 2019 | Not psoriasis |
| Sweetser 2006 | Cross‐over trial |
| Syversen 2020 | NCT03074656 ‐ pragmatic trial according to anti‐TNF dosages |
| Talamonti 2021 | Not a randomised study |
| Talwar 1992 | Not a randomised trial |
| TCTR20190705002 | Comparison of 2 different schemas of administration (same drug same dosage) |
| Tejasvi 2012 | Other treatment |
| Thaçi 2002 | The 2 study arms compared the same molecule with the same dosage |
| Thaçi 2010 | Other treatment |
| Thaçi 2018 | Ineligible outcomes |
| Tong 2008 | Other treatment |
| Tsakok 2018 | Commentary/editorial |
| Vaclavkova 2014 | Another intervention |
| Valenzuela 2017 | Post hoc subgroup analyses of an already included trial |
| Van de Kerkhof 2017 | Post hoc subgroup analyses of an already included trial |
| Van Joost 1988 | Assessment < 8 weeks |
| Vena 2005 | Comparison of 2 schemas of administration |
| Vena 2012 | Other treatment |
| Verma 2021 | Wrong comparator |
| Viglioglia 1978 | Not a trial |
| Viswanath 2022 | Not moderate‐to‐severe psoriasis |
| Witkamp 1995 | Other treatment |
| Wolf 2012 | Other treatment |
| Wright 1966 | Not a randomised trial |
| Wu 2015 | Other treatment |
| Yan 2011 | Another intervention |
| Yesudian 2013 | Other treatment |
| Yiu 2020 | Commentary |
| Yoon 2007 | Dose‐escalation study |
| Yosipovitch 2018 | Not moderate‐to‐severe psoriasis |
| Zachariae 2008 | Other treatment |
| Zhang 2007 | Other treatment |
| Zhang 2009a | Other treatment |
| Zhang 2009b | Other treatment |
| Zhang 2017 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Zhang 2020 | Other treatment, now excluded in this update because interventions no longer meet inclusion criteria |
| Zhang 2022 | Wrong intervention |
| Zhu 2009 | Pooled trials |
| Zhuang 2016 | Phase 1 trial |
| Zobel 1987 | Not a trial |
BSA: body surface area PASI: Psoriasis Area Severity Index RCT: randomised controlled trial TNF: tumour necrosis factor